THREADS OF CROSS-LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.
1 . A thread comprising hyaluronic acid wherein at least a portion of the hyaluronic acid is interlocked and further wherein at least a portion of the hyaluronic acid is cross-linked.
2 . The thread of claim 1 , wherein the thread reflects polarized light.
3 . The thread of claim 1 , wherein the thread has no more than about 30% percent by weight hydration.
4 . The thread of claim 1 , wherein the hyaluronic acid is cross-linked with a cross-linking agent selected from the group consisting of butanediol diglycidyl ether (BDDE), divinyl sulfone (DVS), and 1-ethyl-3-(3-dimethylaminopropyl) carbodimide hydrochloride (EDC), or a combination thereof.
5 . The thread of claim 4 , wherein the cross-linking agent is butanediol diglycidyl ether
(BDDE).
6 . The thread of claim 1 , wherein the thread has an ultimate tensile strength about 5 kpsi or greater.
7 . The thread of claim 6 , wherein the thread has an ultimate tensile strength of about 20 kpsi or greater.
8 . The thread of claim 1 , wherein the thread has a failure of stress of 0.1 pounds or greater.
9 . The thread of claim 1 , wherein the thread is braided, coiled, layered or woven to form a material.
10 . The thread of claim 1 , wherein the thread is substantially cylindrical.
11 . The thread of claim 1 , wherein the thread is substantially D-shaped.
12 . The thread of claim 1 , wherein the thread is substantially ribbon-shaped.
13 . The thread of claim 1 , wherein the thread is substantially ellipsoidal.
14 . The thread of claim 1 , wherein the hyaluronic acid has a molecular weight of from about 0.6 MDa to about 2.6 MDa.
15 . The thread of claim 14 , wherein the hyaluronic acid has a molecular weight of from about 1.4 MDa to about 1.6 MDa.
16 . The thread of claim 1 , wherein the thread further comprises a member selected from the group consisting of a therapeutic agent, a diagnostic agent, a fibrogenesis-enhancing agent, a lubricity-enhancing agent, a biodegradation impeding agent, and combinations thereof.
17 . A method of making a thread comprising hyaluronic acid wherein at least a portion of the hyaluronic acid is interlocked and further wherein at least a portion of the hyaluronic acid is cross-linked, said method comprising drying under ambient conditions an aqueous gel composition comprising hyaluronic acid and a cross-linking agent to provide a dried thread.
18 . The method of claim 17 , wherein the aqueous gel composition is buffered.
19 . The method of claim 18 , wherein the aqueous gel composition has a pH of about 7.
20 . The method of claim 18 , wherein the aqueous gel composition has a pH of about 9.
21 . The method of claim 18 , wherein the aqueous gel composition has a pH of about 10.
22 . The method of claim 21 , further comprising the step of adjusting the pH of the solution with a base.
23 . The method of claim 22 , wherein the base is sodium carbonate or sodium hydroxide.
24 . The method of claim 17 , wherein the composition is provided by adding the cross-linking agent to an aqueous solution comprising hyaluronic acid.
25 . The method of claim 24 , wherein aqueous solution comprises from about 1% to about 30% by weight hyaluronic acid.
26 . The method of claim 25 , wherein the hyaluronic acid has a molecular weight of from about 0.6 MDa to about 2.6 MDa.
27 . The method of claim 25 , wherein the hyaluronic acid has a molecular weight of from about 1.4 MDa to about 1.6 MDa.
28 . The method of claim 24 , wherein from about 0.1 to about 5.0% by volume of cross-linking agent is added to the solution.
29 . The method of claim 24 , wherein from about 0.2 to about 0.8% by volume of cross-linking agent is added to the solution.
30 . The method of claim 17 , wherein the aqueous gel composition has a viscosity of from about 150 Pascal-seconds (Pa·s) to about 2,000 Pascal-seconds (Pa·s).
31 . The method of claim 17 , wherein prior to drying the gel is degassed.
32 . The method of claim 17 , wherein the composition is dried for from about 30 minutes to about 72 hours.
33 . The method of claim 17 , wherein the composition is dried for from about 12 hours to about 24 hours.
34 . The method of claim 17 , further comprising rehydrating the dried thread with an aqueous solvent to form a hydrated thread.
35 . The method of claim 34 , further comprising stretching the hydrated thread.
36 . The method of claim 34 , further comprising re-drying the hydrated thread.
37 . The method of claim 36 , further comprising stretching the rehydrated thread during the re-drying.
38 . The method of claim 36 , wherein the re-drying is performed under ambient conditions.
39 . The method of claim 17 , further comprising applying to the thread a sufficient amount of a member selected from the group consisting of a therapeutic agent, a diagnostic agent, a fibrogenesis-enhancing agent, a biodegradation impeding agent, a lubricity-enhancing agent and combinations thereof, optionally followed by re-drying the thread.
40 . The method of claim 17 , wherein prior to the drying step, the composition is extruded from a syringe onto a substrate to provide a wetted thread.
41 . The method of claim 40 , wherein the composition is extruded from the syringe under pressure.
42 . The method of claim 40 , wherein the substrate is selected from the group consisting of polytetrafluoroethylene (PTFE), expanded PTFE, nylon, polyethylene terephthalate (PET), polystyrene, silicon, polyurethane, and activated cellulose.
43 . The method of claim 42 , wherein the composition and the substrate have an equilibrium contact angle of greater than about 90 degrees.
44 . The method of claim 43 , wherein the substrate is selected so as to provide a substantially cylindrical thread or a substantially ellipsoidal thread.
45 . The method of claim 42 , wherein the composition and the substrate have an equilibrium contact angle of about 90 degrees.
46 . The method of claim 45 , wherein the substrate is selected so as to provide a substantially D-shaped thread.
47 . The method of claim 42 , wherein the composition and the substrate have an equilibrium contact angle of less than about 90 degrees.
48 . The method of claim 47 , wherein the substrate is selected so as to provide a substantially ribbon-shaped thread.
49 . A method of treating a wrinkle in a patient in need thereof, said method comprising;
1) inserting the thread of claim 1 into dermis or subcutaneous space of the patient adjacent to or under the wrinkle; and
2) applying the thread adjacent to or under the wrinkle thereby treating the wrinkle.
50 .- 54 . (canceled)
55 . A kit of parts comprising the thread of claim 1 .
56 .- 59 . (canceled)
60 . A wound dressing comprising the thread of claim 1 .
61 . (canceled)
62 . A wound dressing comprising at least one woven mesh of the thread of claim 1 .
63 .- 65 . (canceled)
66 . An adhesion barrier comprising the thread of claim 1 .
67 . An adhesion barrier comprising at least one woven mesh of the thread of claim 1 .
68 . A wound dressing comprising a pad which conforms to a wound location, an air-tight seal removably adhered to the pad, a negative pressure source in fluid communication with the pad and the thread of claim 1 attached to the wound contacting surface of the pad.
69 . (canceled)
70 . A method of treating a wound in a subject comprising attaching the wound dressing of claim 69 to the wound of the subject in need thereof.
71 . A suture comprised of the thread of claim 1 .
72 . A method of using the suture of claim 71 in surgical applications.
73 . A method of using any one of the thread of claim 1 in surgery applications, ophthalmologic surgery, wound closure, drug delivery and intra-articular injection.
74 . A method of providing facial contouring in a patient in need thereof, said method comprising;
1) inserting the thread of claim 1 into dermis or subcutaneous space of the patient adjacent to or under a treatment location; and
2) applying the thread adjacent to or under the treatment location thereby providing facial contouring.
75 .- 84 . (canceled)